Twentieth Annual Pharmaceutical Compliance Congress Coming April 2023

The 20th Pharmaceutical Compliance Congress (PCC) is scheduled to be delivered as a hybrid event from April 25, 2023, through April 27, 2023, at the Ritz-Carlton, Tysons Corner in McLean, Virginia. The PCC is “the industry’s Gold Standard compliance congress for the life sciences community” and is driven innovation and defined by integrity.

The PCC always offers an unparalleled experience by bringing together industry leaders for discussions, keynotes, and networking. This year’s event will include tactical knowledge exchanges and industry leading benchmarking for compliance professionals, such as product launch considerations, information on creating a compliance guide for ESG, behavioral science, medical and commercial interaction, compliance and the Metaverse, risk assessment and identification, training for compliance teams, data protection and data privacy, and more.

This year, PCC boasts three breakout sessions that are specific to your company type (emerging and small company, mid-large company, and medical device organizations) as well as six workshops designed to address the things that are keeping you up at night (building a compliance program from the ground up; data privacy and protection; closed-door CCO and GC summit; clinical and R&D for compliance; interactive workshop on data and monitoring; and creating a compliance guide to environmental, social, and governance).

Additionally, PCC will offer four education streams to deep-dive into the compliance “hot topics” for the year: market access compliance, risk and monitoring, data and digitization, and professional development and training.

Day One

On Tuesday, April 25, 2023, the PCC will open with a discussion of CMS audits and what to do to prepare for one followed by a Chief Compliance Officer Luminary Panel, featuring five compliance professionals from different perspectives and a Keynote Enforcement Panel, with professionals from private and government offices coming together to provide insight.

In the afternoon, Catherine Gray, Acting Director of the Office of Prescription Drug Promotion at the FDA will provide a Keynote Address, followed by “Crisis Management Best Practices and Preparations,” offered by Seth Lundy and Sally Yates of King & Spaulding. The day closes out with different track offerings, depending on company size and type and then a networking reception.

Day Two

On Wednesday, April 26, 2023, the morning is focused on workshops while the afternoon again offers different track offerings, touching on topics like “Rethinking and Revolutionizing the Compliance Officer Role,” “Options for Reporting Lines to Manage Compliance Risks,” “Navigating the Legal Considerations of Patient Assistance,” and “Living in the New Normal – Navigating Compliance and Investigations in a Post-COVID World.”

Day Three

On Thursday, April 27, 2023, the morning begins with an Empowerment, Diversity, Equity and Inclusion Breakfast Summit followed by working group breakout sessions. James Stansel, Executive Vice President, General Counsel and Corporate Secretary at PhRMA will also speak, discussing the Legislative and Pipeline Report for 2023. The morning will also include a Former Prosecutor Panel and discussion about advancing ethics and innovation.

The afternoon will offer a patient story luminary address, discussion about compliance across the organization, and an innovation ideation wall wrap up session.

Hybrid Event

The event offers two ways to attend: (1) an all-access pass that allows admission to the in-person event and the virtual experience pass, and (2) the virtual experience pass, which allows for access to the ConnectMe virtual platform, live streaming of the general sessions, recorded and PDF presentations (pending speaker permissions) from the in-person event – available for 12 months after the event, and interactive attendee networking via video chat, instant messaging, and meeting request functionalities.

To register click here. Prices will increase on March 31st by $200.

NEW
Comments (0)
Add Comment